Phase 1 Focal Segmental Glomerulosclerosis Clinical Trials
4 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–4 of 4 trials
Recruiting
Phase 1Phase 2
AMPK-activation by Metformin in FSGS: AMP-FSGS
Focal Segmental Glomerulosclerosis
Yale University30 enrolled2 locationsNCT06090227
Recruiting
Phase 1
A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)
Systemic Lupus Erythematosus (SLE)Alopecia Areata (AA)Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)
Otsuka Pharmaceutical Development & Commercialization, Inc.30 enrolled6 locationsNCT06799520
Recruiting
Phase 1
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
Focal Segmental GlomerulosclerosisIgA Nephropathy
Hansoh BioMedical R&D Company84 enrolled1 locationNCT05942625
Completed
Phase 1
R3R01 single dose study in healthy adults
Focal Segmental Glomerulosclerosis
River 3 Renal Corp24 enrolled1 locationACTRN12621001019897